Bank of New York Mellon Corp Has $11.89 Million Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Bank of New York Mellon Corp boosted its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 4.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 931,328 shares of the biopharmaceutical company’s stock after buying an additional 39,513 shares during the period. Bank of New York Mellon Corp’s holdings in Dynavax Technologies were worth $11,893,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of DVAX. US Bancorp DE grew its stake in shares of Dynavax Technologies by 291.4% in the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,034 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 1,457 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in Dynavax Technologies in the 4th quarter worth $71,000. Nisa Investment Advisors LLC grew its position in Dynavax Technologies by 19.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 1,076 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new position in shares of Dynavax Technologies during the 3rd quarter worth about $89,000. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on DVAX. HC Wainwright reiterated a “buy” rating and issued a $31.00 target price on shares of Dynavax Technologies in a research note on Friday, February 21st. William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. The Goldman Sachs Group lowered Dynavax Technologies from a “neutral” rating to a “sell” rating and decreased their price objective for the stock from $15.00 to $12.00 in a report on Tuesday, February 11th. Finally, StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday, February 24th.

Dynavax Technologies Stock Performance

NASDAQ DVAX opened at $13.69 on Friday. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $14.63. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The stock has a market cap of $1.70 billion, a P/E ratio of 76.06 and a beta of 1.23. The company’s 50-day simple moving average is $13.09 and its 200 day simple moving average is $12.28.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting the consensus estimate of $0.05. The company had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. As a group, research analysts forecast that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.